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Purpose: To develop and characterize an oral extended-release matrix tablet of metformin 
hydrochloride using a combination of a hydrophobic carrier and a hydrophilic polymer, and two types of 
formulation techniques. 
Methods: Various metformin hydrochloride formulations containing a hydrophobic carrier (stearic acid) 
and a hydrophilic polymer (polyethylene oxide) were prepared using a 3
2
 factorial design. Two types of 
formulation techniques – melt granulation and direct compression – were evaluated. The influence of the 
carrier, polymer and preparation method on metformin release from the formulations in vitro as well as 
other physicochemical properties were studied. The release data were subjected to various release 
kinetic models and also compared with those of a commercial brand.  
Results: The physicochemical characteristics of all the granules and tablets were generally satisfactory. 
Optimization results indicate that the release rate of metformin HCl was directly proportional to the levels 
of stearic acid (SA) and polyethylene oxide (PEO) in the tablet formulations. Release rate was also 
dependent on the method of granulation used. Kinetic analysis showed that the formulation containing 
30 %w/w of polymer exhibited release similar to that of the commercial brand with a similarity factor (f2) 
of 81.1. Melt granulation was more effective in extending drug release than direct compression. Release 
mechanism followed most closely the Korsemeyer-Peppas model with a correlation coefficient (r
2
) and 
0.991.   
Conclusion: The use of a hydrophobic carrier along with a hydrophilic polymer effectively controls the 
initial rapid release of a highly water soluble drug such as metformin HCl. Hot melt granulation method 
was especially more effective in achieving this than the direct compression method. 
 
Keywords: Metformin hydrochloride, Matrix tablets, Polyethylene oxide, Stearic acid, Hot melt 
granulation, In vitro release. 
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INTRODUCTION 
 
The major therapeutic goals in subjects with 
type 2 diabetes are to optimize blood glucose 
control, reduce overweight, and normalize 
lipid disturbances and elevated blood 
pressure. It has been shown that intensive 
management of type 2 diabetes reduces the 
risk for chronic complications. However, 
pharmacological treatment with oral 
hypoglycemic agents (OHAs) or insulin is 
often required [1]. 
 
Biguanides, in particular, metformin HCI, 
increase sensitivity to insulin in peripheral 
tissues of the hosts. It is also involved in 
inhibition of glucose absorption from the 
intestine, suppression of hepatic 
gluconeogenesis and inhibition of fatty acid 
oxidation [2]. It has an absolute oral 
bioavailability of 40 to 60 % and gastro-
intestinal absorption is apparently complete 
within 6 h of ingestion. An inverse 
relationship is observed between the dose 
ingested and relative absorption with 
therapeutic doses (0.5 to 1.5 g), suggesting 
the involvement of active, saturable 
absorption process [3]. 
 
Plasma half-life of metformin HCl is 1.5 - 4.9 
h [4]. Suitable dosage regimens of the drug 
include unit doses of 500 mg two to three 
times daily and can even be built up to five 
times daily or 850 mg once or twice daily. 
Such multiple dosing regimens are not 
preferred since they lead to patient non--
compliance, potential side effects and danger 
of overdosing. There is, therefore, the need 
to provide formulations and processes that 
would deliver extended release of metformin 
HCI from the dosage form when consumed. 
 
Furthermore, metformin HCl presents 
formulation challenges due to its inherently 
poor compressibility, high dose and high 
water solubility (> 300 mg/ml at 25 ºC). It 
belongs to class III of Biopharmaceutical 
Classification System (BCS) having high 
water solubility and low permeability [5]. For 
drugs that are highly water soluble, both 
hydrophilic and hydrophobic matrix systems 
are widely used in oral controlled release 
drug delivery to obtain a desirable drug 
release. 
 
A direct compression method was reported 
for the preparation of metformin HCl 500 mg 
extended-release tablet [6] but on a 
commercial scale, this may create problems 
of powder flow down the hopper which would 
lead to weight variation, as well as poor 
content uniformity, hardness and friability due 
to its poor compressibility of metformin HCl. 
Sustained release microcapsulated prepa-
ration of metformin HCl using ethyl cellulose 
has been reported to give in vitro release up 
to 22 h; however, preparation of 
microcapsules on commercial scale as well 
as optimization are time-consuming and 
challenging [7]. Several matrix formulations of 
metformin HCl have been reported based on 
the use of a hydrophilic (hydroxypropyl 
methycellulose or carbopol) and/or hydro-
phobic polymers (e.g., ethylcellulose) but no 
effort has been made to compare the 
effectiveness of the production methods.  
 
Waxes have been extensively investigated 
for sustaining the release of drugs. In 
formulating wax matrix systems, different 
processing methods, such as dry blending, 
wet granulation, melt granulation and 
extrusion spheronization, have been used [8-
9]. Melt granulation method can be used for 
granulating water sensitive material and 
producing sustained release granulations. 
This technique fulfills today’s pharmaceutical 
industry need because of its simplicity, 
continuous and efficient process as well as 
many advantages over conventional methods 
of granulations such as wet and dry 
granulation [10,11].  
 
The aim of this work was to prepare matrix 
tablet containing metformin HCl, as a model 
water-soluble drug, using a combination of 
hydrophilic and hydrophobic polymers and 
evaluate its release characteristics. A 
secondary objective was to assess the effect 
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Metformin HCl powder was a gift from USV 
Ltd, Mumbai, India while polyethylene oxide 
(Polyox) was obtained from Colorcon India. 
Microcrystalline cellulose and magnesium 
stearate were purchased from Signet 
Chemicals, India. Other materials used were 
of analytical grade. Glycomet SR 500 mg 
tablets (USV Ltd, Mumbai, India), used as the 
reference metformin sustained release 
tablets, were purchased from a local 
pharmacy. 
 
Full factorial design 
 
Two factors were evaluated, each at three 
levels, and experimental trials were 
performed at all possible concentrations. The 
contents of polyethylene oxide (PEO) and 
stearic acid (SA) were selected as 
independent variables. The diffusion 
exponent (n) and percent drug release at 1 
(Q1), 2 (Q2), 4 (Q4), 8 (Q8), 10 (Q10) and 12 h 
(Q12) were selected as dependent variables. 
The experimental design used is outlined in 
Table 1.  
 
Table 1: Formulation of Metformin HCl matrix 
tablet as per 3
2






ρ1 ρ2 ρ3 
 α1 M1 M2 M3 
α2 M4 M5 M6 SA 
α3 M7 M8 M9 
 
Polyethylene oxide (PEO) concentration: ρ1 
= 10 %; ρ2 = 20 %; ρ3 = 30 %; stearic acid 
(SA) concentration: α1 = 4 %; α2 = 8 %; α3 = 
12 %; each formulation contained: metformin 
HCl – 500 mg, colloidal silicon dioxide – 0.55 
%, magnesium stearate – 0.55 %; 
microcrystalline cellulose - quantity sufficient 
to 900 mg 
 
 
Preparation of matrix tablets by melt 
granulation  
 
Hot melt granulation technique was used to 
prepare the drug-wax matrix formulations. 
First stearic acid was melted in a stainless 
steel vessel at 75 
o
C. Metformin HCl was 
sieved through a 850 µ aperture screen, and 
heated, spread on a metal tray in an oven at 
75 
o
C. Melt granulation was carried out by 
transferring the molten metformin HCl to a 
high shear mixer-granulator (model-Mini 
RMG, Kevin, India) and then slowly adding 
the molten stearic acid. Granulation speed 
was 100 rpm for the impeller and 1500 rpm 
for the chopper while granulation time was 5 
min. The granules were allowed to cool to 
room temperature by spreading them on 
metal trays and then sieved through a 850 µ 
aperture screen. 
 
The melt granules were mixed with PEO (pre-
sieved through a 850 µ screen) and 
microcrystalline cellulose (pre-sieved through 
a 600 µ screen), mixed with colloidal silicon 
dioxide (pre-sieved through a 425 µ screen) 
and magnesium stearate (pre-sieved through 
425 µ screen). The blend was compressed 
into 19 x 9.7 mm oblong tablets in an 8-
station Cadmach compression machine.  
 
Preparation of matrix tablets by direct 
compression  
 
Batch M6 was selected for this purpose. The 
drug and microcrystalline cellulose were 
sieved through a 850 µ screen and manually 
blended for 5 min. Colloidal silicon dioxide 
(pre-sieved through a 425 µ screen) was 
added next and blended for 3 min. Finally 
magnesium stearate (pre-sieved through a 
425 µ screen) was added and mixed for 
additional 2 min. The final blend was 
compressed into 19 x 9.7 mm oblong tablets 
in an 8-station Cadmach compression 
machine.  
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Physicochemical characterization of 
granules 
 
The granules were evaluated for various 
physicochemical parameters including angle 
of repose, bulk density, tap density, 
compressibility index and Hausner ratio. 
 
Angle of repose 
 
The fixed-funnel method was used to 
determine angle of repose. The granule 
formulation was  carefully poured through a 
funnel until the apex of the conical pile just 
touched the tip of funnel. The height (h) of the 
pile of the powder and the radius (r) of its 
conical base were measured and applied to 





 h/r …………….………………  (1) 
 
Bulk and tap densities 
 
A 30 g quantity of the granule samples was 
placed in a 100 ml dry measuring cylinder 
and volume, Vo, occupied by it, without 
tapping, was determined. The cylinder was 
then given 500 taps using a tap density 
apparatus (model ETD-1020, Electrolab, 
India,) and the resulting volume, V500, was 
noted determined [15-16]. The bulk and tap 
densities were calculated using Eqs 2 and 3, 
respectively. 
 
Bulk density = W/Vo…………………… (2) 
Tapped density = W/V500 ………….… (3) 
where W is the weight of the granules. 
 
Compressibility index  
 
This parameter was calculated fitting bulk 
and tap density data (TD and BD, 
respectively) into Eq 4 [15-16]. 




This parameter was calculated as the ratio of 
tap density to bulk density of the granules 
[15-16]. 
 
Physicochemical characterization of 
tablets 
 
The tablets were evaluated for assay, 
hardness and friability. 
 
Determination of drug content 
 
Randomly selected tablets (20) from each 
batch were weighed and powdered. A 
quantity of the powder, equivalent to 100 mg 
of metformin HCl, was transferred to a 100 ml 
volumetric flask and extracted with water. A 
quantity (1 ml) of filtered solution was diluted 
to 100 ml with water and the absorbance 
measured at 233 nm (model UV1201, 
Shimadzu). Each measurement was carried 
out in triplicate and the mean taken. Drug 
concentration was calculated from the 
calibration curve of a standard (concentration 
range: 0 to 10 µg/ml). 
 
Determination of tablet hardness 
 
The hardness of each of 10 tablets randomly 
selected from each batch was measured with 
a tablet hardness tester, and the mean and 
standard deviation evaluation. 
 
Determination of tablet friability 
 
Tablet friability was assessed using a 
friabilator (model EF-2, Electrolab, India) at 
25 rpm for 4 min. The weight of ten tablets 
before and after the test, and the percent loss 
in weight recorded as friability.  
 
Evaluation of in-vitro drug release 
 
In-vitro drug release assessment was 
performed using USP type I (basket) 
apparatus in 900 ml of 0.1M HCl at 37± 5 ºC 
for the first hour and then with phosphate 
buffer pH 6.8 for a further 11 h, with the 
apparatus rotating at 100 rpm throughout the 
test. Samples were withdrawn at 
predetermined time intervals and replaced 
with an equivalent volume of fresh dissolution 
medium. The withdrawn samples were 
filtered through a 0.45 µm membrane filter, 
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suitably diluted and analyzed at 233 nm for 
metformin HCl by UV-spectrophotometer 
(Shimadzu UV1201). The content of drug and 
the cumulative percent drug release were 
derived from a standard metformin HCL 
calibration curve. 
 
Kinetic analysis of drug release data 
 
To analyze the in vitro release data, various 
kinetic models, including zero order (Eq 5) 
[17], first order (Eq 6) [18], Higuchi (Eq 7) 
[19], and Hixson-Crowell cube root law (Eq 8) 
[20]. 
 
C = kot … … … ....  … … … … … … .… (5) 
 
where, K0 is zero-order rate constant 
expressed in units of concentration/time and t 
is the time. 
Log C = Log C0 kt/2.303 … … … … …… (6) 
 
where, C0 is the initial concentration of the 
drug and K is first order rate constant. 
Q = Kt
1/ 2
  ….……………………………….  (7) 
 
where, K is the constant reflecting the design 
variables of the system. 
Q0 
1/3
 – Qt 
1/3
 = KHC t … … ………………..  (8) 
 
where, Qt is the amount of drug released in 
time t, Q0 is the initial amount of the drug in 
tablet and KHC is the rate constant for Hixson-
Crowell rate equation. 
 
Mechanism of drug release 
 
A simple relationship, Korsmeyer–Peppas 
model [21], was applied to determine the 
mechanism of drug release as in Eq 9. 
Mt/M∞= Kt
n
 ………………………………  (9) 
 
where Mt/M∞ is the fraction of drug released 
at time t, K is the rate constant and n is the 
release exponent. The n value was used to 
characterize different release mechanisms for 
cylindrical shaped matrices. 
 
Assessment of similarity factor  
 
Similarity factor (ƒ2), computed as in Eq 10, 
was used to compare differences in drug 
release profile. Similarity factor (ƒ2) values 
between 50 and 100 indicate equivalence of 
two sets of release data [22-23]. 
 
ƒ2 = 50 log { (1 + 1/n∑ 
n





× 100 } ………………… …………….  (10) 
 
where Rt and Tt represent the dissolution 





Statistical evaluation was performed by 
analysis of variance (ANOVA) using Microsoft 
Office Excel 2003. The confidence limit was 
set at 95%. Regression coefficient (R
2
) was 
used to determine how well a regression 
model describes the release data. Mean ± 
SD for tablet thickness, weight and hardness 





Evaluation of granules 
 
Table 2 summarizes the physicochemical 
properties (bulk density, tapped density, 
angle of repose, Carr’s index and Hausner 
ratio) of the granules.  
 






















































































M1 0.53 0.66 39.8 19.7 1.25 
M2 0.56 0.69 36.6 18.8 1.23 
M3 0.61 0.74 38.0 17.6 1.21 
M4 0.54 0.67 38.1 19.4 1.24 
M5 0.57 0.7 37.3 18.6 1.23 
M6 0.63 0.76 35.8 17.1 1.21 
M7 0.55 0.67 37.2 17.9 1.22 
M8 0.59 0.73 37.5 19.2 1.24 
M9 0.65 0.78 35.6 16.7 1.20 
DC 0.51 0.64 41.2 20.3 1.25 
 
The bulk density of the granules ranged from 
0.51 - 0.65 gm/ml and tapped density from 
0.64 - 0.78 g/ml. The angle of repose of the 
granules prepared by melt granulation 
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method was in the range 35.6 - 39.8º while it 
was 41.2º for the direct compression 
granules. The compressibility (Carr’s index) 
for all the formulations was < 25 % while 
Hausner ratio was in the range 1.20 -1.25. 
 
Physicochemical characteristics of 
metformin tablets 
 
Table 3 indicates the results of the various 
physicochemical tests (hardness, friability 
and assay) performed on the tablet 
formulations. 
 















M1 80 ± 4 0.21 99.92 
M2 78 ± 4 0.25 99.96 
M3 74 ± 4 0.31 100.10 
M4 75 ±2.83 0.28 100.02 
M5 74 ± 3.95 0.26 99.97 
M6 76 ± 2.07 0.19 99.95 
M7 79 ± 2.62 0.21 98.20 
M8 75 ± 4.14 0.23 99.20 
M9 70 ± 4.58 0.28 97.85 
DC 66 ± 5.74 0.42 99.58 
 
a
Mean ± SD  
 
The hardness of the tablets produced by melt 
granulation (formulation M1 – M9) and direct 
compression (formulation DC) was in the 
range 70 - 80 N for the former and 66 N for 
the latter. All the formulations showed less 
than 1 % friability which is within the 
prescribed limit. Drug content was uniform 
within each batch and ranged from 97.85 – 
100.10 % of the theoretical value. 
 
Evaluation of in-vitro release 
 
The in-vitro drug release results for the test 
and reference (commercial brand) tablets are 
shown in Figs 1 and 2.  
 
The release results for the formulations 
composed of polyethylene oxide (PEO) in the 
range of 10, 20, 30 % w/w and stearic acid 
(SA) in the range of 4, 8, 12% w/w are shown 
in Figs 1 and 2. Over the period of 12 h, the 
drug release rate for M1 and M9 formulations 
decreased as the concentration of 
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Fig 1: Comparative release profiles of metformin 
HCl tablets with varying PEO content (a): M1= X; 
M2 = ■; M3 = ▲; and (b) M4= X; M5 = ■; M6 = ▲; 
DC = ж; reference (commercial) product = o 
 
The release profile of M6 formulation (which 
contains 30 %w/w of PEO and 8% w/w of SA) 
is similar to that of the reference 
(commercial) product based on the similarity 
factor (f2) value of 81.08. Kinetic analysis of 
the release data indicates that formulation M6 
fitted best to both Higuchi and Korsemeyer-
Peppas models with correlation coefficients 
of 0.9780 and 0.9910, respectively, and n 
value of 0.4967. 
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Fig 2: Comparative release profiles of metformin 
HCl with (a) varying PEO content: M7 = X; M8 = ■; 
M9 =▲; reference (commercial) product = o; and 





A suitable extended release metformin HCl 
dosage form would not only enhance 
therapeutic efficacy and patient compliance 
but also produce more desirable blood drug 
levels and lower incidence of adverse effects. 
  
The density of a material depends on the 
shape and size of the particles. The density is 
normally proportional to the number of 
spherical particles present in the bulk, and 
inversely proportional to the size of particles 
[24]. Notwithstanding this, out of all the nine 
granule formulations, M9 (the optimized 
formulation) had the largest granules, as well 
as the highest bulk and tapped densities 
(Table 2). M9 granules were probably more 
regular in shape, producing a more uniform 
distribution, with smaller void spaces 
between the particles. Carr’s index (CI) is 
usually indicative of the flowability and 
degree of packing of the material; these are 
important parameters when filling a matrix 
formulation into the die of the tablet press. A 
CI of < 15 % indicates adequate granule flow 
and stable packing, while values > 25 % are 
characteristic of poor flow properties. The 
Hausner ratio is usually related to the 
compressibility of powder and values < 1.25 
are indicative of good compressibility. All the 
formulations had CI < 25 % and Hausner 
ratio ≤ 1.25 indicating good to passable flow 
irrespective of the method of granulation. 
 
The drug content of all the formulations 
ranged from 98.2 -100.1 %, indicating the 
presence of an acceptable amount of drug in 
the formulations. Furthermore, all the 
formulations showed satisfactory hardness 
and friability. 
 
The decrease in drug release rate as the 
concentration of polyethylene oxide increase 
is consistent with the findings of Rajkumar at 
el [25], which indicate that the presence of a 
highly water soluble compound in 
polyethylene oxide matrix results in a faster 
rate of polymer swelling and a large increase 
in gel thickness to prevent immediate tablet 
disintegration, and thus controlling the 
diffusion of the drug. Increase in polymer 
concentration not only caused increase in the 
viscosity of the gel but also led to a decrease 
in the diffusion of drug and, therefore, a 
reduction in the drug release rate [26]. Other 
factors at play in relation to polymer content 
probably include change in water penetration 
rate, water absorption capacity and polymer 
swelling [27]. 
 
Also, the decrease in drug release rate when 
the stearic acid content of the matrix was 
increased may be due to slower penetration 
Nanjwade et al 
Trop J Pharm Res, August 2011;10 (4): 382 
of the dissolution medium in matrices as a 
result of increased lipophilicity [28] while the 
initial burst release from the matrix can 
probably be attributed to the dissolution of 
drug from the tablet surface. Further, 
penetration of dissolution fluid was hindered 
by the hydrophobic coating of stearic acid 
around the drug particles, leading to 
diminished drug release over an extended 
period [29].  
 
The slower drug release from the tablets 
derived by melt granulation (compared with 
those prepared by direct compression) could 
be due to the formation of a more uniform, 
and hence, a more effective and rigid 
hydrophobic coating of stearic acid around 
the hydrophilic drug particles during hot melt 
granulation.  
 
An ideal matrix formulation should contain 
polymers and diluents at amounts as little as 
possible, and release its drug content in a 
sustained release profile over a reasonable 
length of time, preferably by zero-order 
kinetics [30]. On fitting M6 data into various 
release models, the highest regression 
coefficients, 0.9780 and 0.9910, were for 
Higuchi and Korsemeyer-Peppas models, 
respectively, with n value of 0.4967 which 
indicates a coupling of diffusion and erosion 
mechanism, so-called anomalous diffusion. 
This iindicates, therefore, that drug release 
from the tablets was controlled more by 
polymer swelling, followed by drug diffusion 
through the swollen polymer, and then slow 




An extended release tablet formulation of 
metformin HCl was successfully developed 
using a combination of hydrophobic and 
hydrophilic polymers. The matrix tablet 
formulation demonstrated the desired drug 
release profile. Melt granulation is more 
effective than direct compression for 
controlling the release of a highly water 
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